CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial

CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment

Excerpt from the Press Release:

SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in a Phase 1 clinical trial. The company is developing CuraAX for patients with neurogenicorthostatic hypotension (nOH). Neurogenic orthostatic hypotension is a condition characterized by a significant, sudden drop in blood pressure upon standing, resulting in debilitating dizziness, fainting and cognitive impairment, due to inadequate blood flow to the brain. CuraAX is also expected to benefit cognition in patients with a range of neurologic conditions.

CuraAX, also known as CST-3056, is a proprietary, selective, CNS-penetrant alpha-1A adrenoceptor (α_1A-AR) agonist. The Phase 1 trial, whose objective is to assess the safety, tolerability and pharmacokinetics of CuraAX, will evaluate multiple dose levels of CuraAX in approximately 56 healthy volunteers, with an additional food effect cohort of six patients. The study will monitor a range of pharmacodynamic effects associated with α_1A-AR agonism to assess target engagement and potential therapeutic impact in nOH patients, as well as inform Phase 2 dose selection. Many patients with Parkinson’s disease and related neurological disorders are affected by nOH.

“Current treatments for nOH are limited given their non-selectivity and/or indirect mode of action, leading to significant side effects; additionally, dosing regimens for standard of care products are demanding. C

Click the button below to read the entire Press Release:

Continue Reading The Press Release